508 related articles for article (PubMed ID: 31619522)
1. Activin A receptor type 1-mediated BMP signaling regulates RANKL-induced osteoclastogenesis via canonical SMAD-signaling pathway.
Omi M; Kaartinen V; Mishina Y
J Biol Chem; 2019 Nov; 294(47):17818-17836. PubMed ID: 31619522
[TBL] [Abstract][Full Text] [Related]
2. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
[TBL] [Abstract][Full Text] [Related]
3. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
Li L; Sapkota M; Gao M; Choi H; Soh Y
Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
[TBL] [Abstract][Full Text] [Related]
4. BmpR1A is a major type 1 BMP receptor for BMP-Smad signaling during skull development.
Pan H; Zhang H; Abraham P; Komatsu Y; Lyons K; Kaartinen V; Mishina Y
Dev Biol; 2017 Sep; 429(1):260-270. PubMed ID: 28641928
[TBL] [Abstract][Full Text] [Related]
5. Bone morphogenetic proteins signal via SMAD and mitogen-activated protein (MAP) kinase pathways at distinct times during osteoclastogenesis.
Broege A; Pham L; Jensen ED; Emery A; Huang TH; Stemig M; Beppu H; Petryk A; O'Connor M; Mansky K; Gopalakrishnan R
J Biol Chem; 2013 Dec; 288(52):37230-40. PubMed ID: 24235143
[TBL] [Abstract][Full Text] [Related]
6. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
7. MKP-1 signaling events are required for early osteoclastogenesis in lineage defined progenitor populations by disrupting RANKL-induced NFATc1 nuclear translocation.
Valerio MS; Herbert BA; Griffin AC; Wan Z; Hill EG; Kirkwood KL
Bone; 2014 Mar; 60():16-25. PubMed ID: 24269279
[TBL] [Abstract][Full Text] [Related]
8. Homer2 and Homer3 modulate RANKL-induced NFATc1 signaling in osteoclastogenesis and bone metabolism.
Son A; Kang N; Oh SY; Kim KW; Muallem S; Yang YM; Shin DM
J Endocrinol; 2019 Sep; 242(3):241-249. PubMed ID: 31319381
[TBL] [Abstract][Full Text] [Related]
9. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
10. WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling.
Chen C; Qin Y; Fang JP; Ni XY; Yao J; Wang HY; Ding K
Acta Pharmacol Sin; 2015 Sep; 36(9):1053-64. PubMed ID: 26299951
[TBL] [Abstract][Full Text] [Related]
11. Enhanced osteoclastogenesis causes osteopenia in twisted gastrulation-deficient mice through increased BMP signaling.
Sotillo Rodriguez JE; Mansky KC; Jensen ED; Carlson AE; Schwarz T; Pham L; MacKenzie B; Prasad H; Rohrer MD; Petryk A; Gopalakrishnan R
J Bone Miner Res; 2009 Nov; 24(11):1917-26. PubMed ID: 19419314
[TBL] [Abstract][Full Text] [Related]
12. Acvr1 deletion in osteoblasts impaired mandibular bone mass through compromised osteoblast differentiation and enhanced sRANKL-induced osteoclastogenesis.
Hu Y; Hao X; Liu C; Ren C; Wang S; Yan G; Meng Y; Mishina Y; Shi C; Sun H
J Cell Physiol; 2021 Jun; 236(6):4580-4591. PubMed ID: 33251612
[TBL] [Abstract][Full Text] [Related]
13. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
[TBL] [Abstract][Full Text] [Related]
14. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
15. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
Okamoto M; Murai J; Yoshikawa H; Tsumaki N
J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca
Cao B; Dai X; Wang W
J Cell Physiol; 2019 May; 234(5):6831-6841. PubMed ID: 30387123
[TBL] [Abstract][Full Text] [Related]
17. Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways.
Yamashita T; Uehara S; Udagawa N; Li F; Kadota S; Esumi H; Kobayashi Y; Takahashi N
PLoS One; 2014; 9(1):e85878. PubMed ID: 24465763
[TBL] [Abstract][Full Text] [Related]
18. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
19. Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro.
Fong D; Bisson M; Laberge G; McManus S; Grenier G; Faucheux N; Roux S
Cell Signal; 2013 Apr; 25(4):717-28. PubMed ID: 23313128
[TBL] [Abstract][Full Text] [Related]
20. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
